{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:36:39Z","timestamp":1792697799667,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014761","name":"Natural Science Foundation of Qingdao Municipality","doi-asserted-by":"publisher","award":["23-2-1-158-zyyd-jch"],"award-info":[{"award-number":["23-2-1-158-zyyd-jch"]}],"id":[{"id":"10.13039\/501100014761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["202264006"],"award-info":[{"award-number":["202264006"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["11701538"],"award-info":[{"award-number":["11701538"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Accurate prediction of anticancer drug responses remains a significant challenge due to the intricate interplay between genomic features and pharmacological mechanisms. We present Matrix Completion with Low-rank Regularization and Principal Component Analysis (MCLRP), a multimodal framework that synergistically integrates low-rank matrix completion with transcriptomic principal component analysis through dual-stream feature interaction. This innovative architecture not only leverages the similarities among drugs and mutation patterns in cell lines via matrix completion but also preserves gene-level interpretability of response patterns by incorporating gene expression data into the model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Benchmarked against seven computational paradigms (including matrix completion, ridge regression, SRMF, and their hybrid variants) across the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE) repositories, MCLRP demonstrated superior predictive performance for 75% of drug responses, alongside enhanced biological plausibility. Notably, the model identified imatinib as a potential therapeutic alternative for M14 melanoma cell lines through cross-drug response extrapolation, suggesting innovative strategies for overcoming doxorubicin resistance. Interestingly, our mutation-response mapping revealed that BRAF-mutated lineages exhibited a 4.7-fold increase in sensitivity (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20091e-5) to AZ628 compared to wild-type lineages, with synergistic amplification (8.1-fold,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20091e-7) observed in BRAF\/PIK3CA co-mutants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings establish MCLRP as a dual-purpose predictive-analytical tool that not only enhances drug response forecasting but also uncovers mutation-specific pharmacological vulnerabilities through systems-level pattern recognition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12915-025-02457-8","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:38:18Z","timestamp":1764743898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["MCLRP: enhanced prediction of anticancer drug response through low-rank matrix completion and transcriptomic profiling"],"prefix":"10.1186","volume":"24","author":[{"given":"Kun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binhan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dailin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"6","key":"2457_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1056\/NEJMp1114866","volume":"366","author":"R Mirnezami","year":"2012","unstructured":"Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med. 2012;366(6):489\u201391.","journal-title":"N Engl J Med"},{"issue":"3","key":"2457_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1158\/1078-0432.CCR-13-2127","volume":"20","author":"G Xiao","year":"2014","unstructured":"Xiao G, et al. Adaptive prediction model in prospective molecular signature-based clinical studies. Clin Cancer Res. 2014;20(3):531\u20139.","journal-title":"Clin Cancer Res"},{"issue":"7391","key":"2457_CR3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature11005","volume":"483","author":"MJ Garnett","year":"2012","unstructured":"Garnett MJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483(7391):570\u20135.","journal-title":"Nature"},{"issue":"7391","key":"2457_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603\u20137.","journal-title":"Nature"},{"issue":"3","key":"2457_CR5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","volume":"166","author":"F Iorio","year":"2016","unstructured":"Iorio F, et al. A landscape of pharmacogenomic interactions in cancer. Cell. 2016;166(3):740\u201354.","journal-title":"Cell"},{"issue":"14","key":"2457_CR6","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-12-1370","volume":"72","author":"WC Reinhold","year":"2012","unstructured":"Reinhold WC, et al. Cell miner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 2012;72(14):3499\u2013511.","journal-title":"Cancer Res"},{"key":"2457_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.omtn.2020.07.003","volume":"21","author":"C Liu","year":"2020","unstructured":"Liu C, et al. An improved anticancer drug-response prediction based on an ensemble method integrating matrix completion and ridge regression. Mol Ther Nucleic Acids. 2020;21:676\u201386.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2457_CR8","doi-asserted-by":"publisher","unstructured":"Geeleher P, Cox NJ, Huang RS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol. 2014;15: R47. https:\/\/doi.org\/10.1186\/gb-2014-15-3-r47.","DOI":"10.1186\/gb-2014-15-3-r47"},{"issue":"1","key":"2457_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-021-04146-z","volume":"22","author":"S Park","year":"2021","unstructured":"Park S, Soh J, Lee H. Super.FELT: supervised feature extraction learning using triplet loss for drug response prediction with multi-omics data. BMC Bioinformatics. 2021;22(1):269.","journal-title":"BMC Bioinformatics"},{"issue":"2","key":"2457_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1109\/TCBB.2019.2919581","volume":"18","author":"M Li","year":"2021","unstructured":"Li M, et al. Deepdsc: a deep learning method to predict drug sensitivity of cancer cell lines. IEEE ACM Trans Comput Biol Bioinform. 2021;18(2):575\u201382.","journal-title":"IEEE ACM Trans Comput Biol Bioinform"},{"issue":"1","key":"2457_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1389450120666190923162203","volume":"21","author":"K Li","year":"2020","unstructured":"Li K, et al. Bioinformatics approaches for anti-cancer drug discovery. Curr Drug Targets. 2020;21(1):3\u201317.","journal-title":"Curr Drug Targets"},{"key":"2457_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12864-021-07524-2","volume":"22","author":"V Malik","year":"2021","unstructured":"Malik V, Kalakoti Y, Sundar D. Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer. BMC Genomics. 2021;22:1\u201311.","journal-title":"BMC Genomics"},{"issue":"8","key":"2457_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11082251","volume":"11","author":"M Shahab","year":"2023","unstructured":"Shahab M, et al. Machine learning-based virtual screening and molecular simulation approaches identified novel potential inhibitors for cancer therapy. Biomedicines. 2023;11(8):2251.","journal-title":"Biomedicines"},{"key":"2457_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/srep22811","volume":"6","author":"X Liu","year":"2016","unstructured":"Liu X, et al. A systematic study on drug-response associated genes using baseline gene expressions of the Cancer Cell Line Encyclopedia. Sci Rep. 2016;6:22811.","journal-title":"Sci Rep"},{"issue":"2","key":"2457_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab581","volume":"23","author":"Y Meng","year":"2022","unstructured":"Meng Y, et al. A weighted bilinear neural collaborative filtering approach for drug repositioning. Brief Bioinform. 2022;23(2):bbab581.","journal-title":"Brief Bioinform"},{"issue":"3","key":"2457_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004790","volume":"12","author":"A Sokolov","year":"2016","unstructured":"Sokolov A, et al. Pathway-based genomics prediction using generalized elastic net. PLoS Comput Biol. 2016;12(3):e1004790.","journal-title":"PLoS Comput Biol"},{"key":"2457_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603615","volume":"11","author":"X Tang","year":"2020","unstructured":"Tang X, et al. Indicator regularized non-negative matrix factorization method-based drug repurposing for COVID-19. Front Immunol. 2020;11:603615.","journal-title":"Front Immunol"},{"issue":"1","key":"2457_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3500-5","volume":"17","author":"L Wang","year":"2017","unstructured":"Wang L, et al. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization. BMC Cancer. 2017;17(1):513.","journal-title":"BMC Cancer"},{"key":"2457_CR19","first-page":"164","volume":"17","author":"NN Guan","year":"2019","unstructured":"Guan NN, et al. Anticancer drug response prediction in cell lines using weighted graph regularized matrix factorization. Mol Ther. 2019;17:164\u201374.","journal-title":"Mol Ther"},{"issue":"20","key":"2457_CR20","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1093\/bioinformatics\/btx390","volume":"33","author":"L Huang","year":"2017","unstructured":"Huang L, et al. Matrix completion with side information and its applications in predicting the antigenicity of influenza viruses. Bioinformatics. 2017;33(20):3195\u2013201.","journal-title":"Bioinformatics"},{"issue":"17","key":"2457_CR21","doi-asserted-by":"publisher","first-page":"i455","DOI":"10.1093\/bioinformatics\/btw433","volume":"32","author":"M Ammad-Ud-Din","year":"2016","unstructured":"Ammad-Ud-Din M, et al. Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization. Bioinformatics. 2016;32(17):i455\u201363.","journal-title":"Bioinformatics"},{"issue":"1","key":"2457_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/bib\/bbz164","volume":"22","author":"J Chen","year":"2021","unstructured":"Chen J, Zhang L. A survey and systematic assessment of computational methods for drug response prediction. Brief Bioinform. 2021;22(1):232\u201346.","journal-title":"Brief Bioinform"},{"issue":"2","key":"2457_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12539-024-00668-1","volume":"17","author":"J Song","year":"2025","unstructured":"Song J, et al. Drug sensitivity prediction based on multi-stage multi-modal drug representation learning. Interdiscip Sci Comput Life Sci. 2025;17(2):231\u201343.","journal-title":"Interdiscip Sci Comput Life Sci"},{"key":"2457_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1086097","volume":"10","author":"A Partin","year":"2023","unstructured":"Partin A, et al. Deep learning methods for drug response prediction in cancer: predominant and emerging trends. Front Med. 2023;10:1086097.","journal-title":"Front Med"},{"key":"2457_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.physa.2023.128585","volume":"615","author":"LF Scabini","year":"2023","unstructured":"Scabini LF, Bruno OM. Structure and performance of fully connected neural networks: emerging complex network properties. Physica A Stat Mech Appl. 2023;615:128585.","journal-title":"Physica A Stat Mech Appl"},{"issue":"1","key":"2457_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18197-y","volume":"11","author":"O Bazgir","year":"2020","unstructured":"Bazgir O, et al. Representation of features as images with neighborhood dependencies for compatibility with convolutional neural networks. Nat Commun. 2020;11(1):4391.","journal-title":"Nat Commun"},{"issue":"24","key":"2457_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20246276","volume":"20","author":"M Joo","year":"2019","unstructured":"Joo M, et al. A deep learning model for cell growth inhibition IC50 prediction and its application for gastric cancer patients. Int J Mol Sci. 2019;20(24):6276.","journal-title":"Int J Mol Sci"},{"issue":"Supplement_2","key":"2457_CR28","doi-asserted-by":"publisher","first-page":"i911","DOI":"10.1093\/bioinformatics\/btaa822","volume":"36","author":"Q Liu","year":"2020","unstructured":"Liu Q, et al. DeepCDR: a hybrid graph convolutional network for predicting cancer drug response. Bioinformatics. 2020;36(Supplement_2):i911\u20138.","journal-title":"Bioinformatics"},{"issue":"1","key":"2457_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90923-y","volume":"11","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, et al. Converting tabular data into images for deep learning with convolutional neural networks. Sci Rep. 2021;11(1):11325.","journal-title":"Sci Rep"},{"issue":"3","key":"2457_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac100","volume":"23","author":"L Jiang","year":"2022","unstructured":"Jiang L, et al. Deeptta: a transformer-based model for predicting cancer drug response. Brief Bioinform. 2022;23(3):bbac100.","journal-title":"Brief Bioinform"},{"key":"2457_CR31","unstructured":"Oskooei A, et al. PaccMann: prediction of anticancer compound sensitivity with multi-modal attention-based neural networks. arXiv:1811.06802 [cs.LG]. 2018. Available from: https:\/\/arxiv.org\/abs\/1811.06802."},{"issue":"2","key":"2457_CR32","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1109\/TCBB.2022.3206888","volume":"20","author":"T Chu","year":"2022","unstructured":"Chu T, et al. Graph transformer for drug response prediction. IEEE\/ACM Trans Comput Biol Bioinform. 2022;20(2):1065\u201372.","journal-title":"IEEE\/ACM Trans Comput Biol Bioinform"},{"issue":"Suppl 4","key":"2457_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-022-04664-4","volume":"23","author":"T Ma","year":"2022","unstructured":"Ma T, et al. DualGCN: a dual graph convolutional network model to predict cancer drug response. BMC Bioinformatics. 2022;23(Suppl 4):129.","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"2457_CR34","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s12539-023-00596-6","volume":"16","author":"S Yan","year":"2024","unstructured":"Yan S, Zheng D. A deep neural network for predicting synergistic drug combinations on cancer. Interdiscip Sci Comput Life Sci. 2024;16(1):218\u201330.","journal-title":"Interdiscip Sci Comput Life Sci"},{"key":"2457_CR35","unstructured":"Jin W, Barzilay R, Jaakkola T. Junction tree variational autoencoder for molecular graph generation. In: Proceedings of the 35th International Conference on Machine Learning. PMLR. 2018:2323\u201332."},{"issue":"1","key":"2457_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab356","volume":"23","author":"F Xia","year":"2022","unstructured":"Xia F, et al. A cross-study analysis of drug response prediction in cancer cell lines. Brief Bioinform. 2022;23(1):bbab356.","journal-title":"Brief Bioinform"},{"issue":"2","key":"2457_CR37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s43018-020-00169-2","volume":"2","author":"J Ma","year":"2021","unstructured":"Ma J, et al. Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients. Nat Cancer. 2021;2(2):233\u201344.","journal-title":"Nat Cancer"},{"issue":"1","key":"2457_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74921-0","volume":"10","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, et al. Ensemble transfer learning for the prediction of anti-cancer drug response. Sci Rep. 2020;10(1):18040.","journal-title":"Sci Rep"},{"key":"2457_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-021-04352-9","volume":"22","author":"Z Zuo","year":"2021","unstructured":"Zuo Z, et al. SWnet: a deep learning model for drug response prediction from cancer genomic signatures and compound chemical structures. BMC Bioinformatics. 2021;22:1\u201316.","journal-title":"BMC Bioinformatics"},{"issue":"14","key":"2457_CR40","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1093\/bioinformatics\/btac383","volume":"38","author":"DE Hostallero","year":"2022","unstructured":"Hostallero DE, Li Y, Emad A. Looking at the BiG picture: incorporating bipartite graphs in drug response prediction. Bioinformatics. 2022;38(14):3609\u201320.","journal-title":"Bioinformatics"},{"issue":"3","key":"2457_CR41","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.gpb.2023.01.006","volume":"21","author":"DE Hostallero","year":"2023","unstructured":"Hostallero DE, et al. Preclinical-to-clinical anti-cancer drug response prediction and biomarker identification using TINDL. Genomics Proteomics Bioinformatics. 2023;21(3):535\u201350.","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"1","key":"2457_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1007607","volume":"16","author":"EW Huang","year":"2020","unstructured":"Huang EW, et al. Tissue-guided LASSO for prediction of clinical drug response using preclinical samples. PLoS Comput Biol. 2020;16(1):e1007607.","journal-title":"PLoS Comput Biol"},{"issue":"5","key":"2457_CR43","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ccell.2020.09.014","volume":"38","author":"BM Kuenzi","year":"2020","unstructured":"Kuenzi BM, et al. Predicting drug response and synergy using a deep learning model of human cancer cells. Cancer Cell. 2020;38(5):672\u2013684.e6.","journal-title":"Cancer Cell"},{"key":"2457_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fbinf.2021.639349","volume":"1","author":"H Zhang","year":"2021","unstructured":"Zhang H, Chen Y, Li F. Predicting anticancer drug response with deep learning constrained by signaling pathways. Front Bioinform. 2021;1:639349.","journal-title":"Front Bioinform"},{"issue":"1","key":"2457_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08283-9","volume":"21","author":"G Ning","year":"2021","unstructured":"Ning G, et al. A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer. BMC Cancer. 2021;21(1):923.","journal-title":"BMC Cancer"},{"issue":"7","key":"2457_CR46","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s10585-011-9398-4","volume":"28","author":"K Furugaki","year":"2011","unstructured":"Furugaki K, et al. Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292. Clin Exp Metastasis. 2011;28(7):649\u201359.","journal-title":"Clin Exp Metastasis"},{"issue":"10","key":"2457_CR47","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1016\/j.celrep.2018.05.016","volume":"23","author":"AD Jenks","year":"2018","unstructured":"Jenks AD, et al. Primary cilia mediate diverse kinase inhibitor resistance mechanisms in cancer. Cell Rep. 2018;23(10):3042\u201355.","journal-title":"Cell Rep"},{"issue":"7","key":"2457_CR48","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/cas.12171","volume":"104","author":"M Kurokawa","year":"2013","unstructured":"Kurokawa M, et al. Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes. Cancer Sci. 2013;104(7):904\u201311.","journal-title":"Cancer Sci"},{"issue":"11","key":"2457_CR49","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nrm1498","volume":"5","author":"C Wellbrock","year":"2004","unstructured":"Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875\u201385.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"2457_CR50","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/nm.3392","volume":"19","author":"P Lito","year":"2013","unstructured":"Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013;19(11):1401\u20139.","journal-title":"Nat Med"},{"key":"2457_CR51","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1477-3163-3-6","volume":"3","author":"R Houben","year":"2004","unstructured":"Houben R, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog. 2004;3:6.","journal-title":"J Carcinog"},{"issue":"12","key":"2457_CR52","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1245\/s10434-010-1129-6","volume":"17","author":"KL Lin","year":"2010","unstructured":"Lin KL, et al. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol. 2010;17(12):3294\u2013300.","journal-title":"Ann Surg Oncol"},{"key":"2457_CR53","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317706230","author":"P Sadlecki","year":"2017","unstructured":"Sadlecki P, et al. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers. Tumour Biol. 2017. https:\/\/doi.org\/10.1177\/1010428317706230.","journal-title":"Tumour Biol"},{"issue":"8","key":"2457_CR54","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1593\/neo.09398","volume":"11","author":"L Ciuffreda","year":"2009","unstructured":"Ciuffreda L, et al. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia. 2009;11(8):720\u201331.","journal-title":"Neoplasia"},{"issue":"12","key":"2457_CR55","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1002\/ijc.25304","volume":"127","author":"D Liu","year":"2010","unstructured":"Liu D, et al. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer. 2010;127(12):2965\u201373.","journal-title":"Int J Cancer"},{"issue":"23","key":"2457_CR56","doi-asserted-by":"publisher","first-page":"11100","DOI":"10.1158\/0008-5472.CAN-06-2554","volume":"66","author":"AJ King","year":"2006","unstructured":"King AJ, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 2006;66(23):11100\u20135.","journal-title":"Cancer Res"},{"issue":"12","key":"2457_CR57","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1517\/14728222.11.12.1587","volume":"11","author":"V Khazak","year":"2007","unstructured":"Khazak V, et al. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets. 2007;11(12):1587\u2013609.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"2457_CR58","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF03401664","volume":"3","author":"WD Foulkes","year":"1997","unstructured":"Foulkes WD, et al. The CDKN2A (p16) gene and human cancer. Mol Med. 1997;3(1):5\u201320.","journal-title":"Mol Med"},{"issue":"3 Suppl 7","key":"2457_CR59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0093-7754(03)70011-6","volume":"30","author":"RW Akita","year":"2003","unstructured":"Akita RW, Sliwkowski MX. Preclinical studies with erlotinib (Tarceva). Semin Oncol. 2003;30(3 Suppl 7):15\u201324.","journal-title":"Semin Oncol"},{"issue":"41","key":"2457_CR60","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","volume":"21","author":"W Xia","year":"2002","unstructured":"Xia W, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR\/erbB2 and downstream Erk1\/2 and AKT pathways. Oncogene. 2002;21(41):6255\u201363.","journal-title":"Oncogene"},{"issue":"5","key":"2457_CR61","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1007\/s10637-011-9763-9","volume":"30","author":"JH Cho","year":"2012","unstructured":"Cho JH, et al. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs. 2012;30(5):2008\u201314.","journal-title":"Invest New Drugs"},{"issue":"16","key":"2457_CR62","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1158\/1078-0432.CCR-07-0484","volume":"13","author":"T Guo","year":"2007","unstructured":"Guo T, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res. 2007;13(16):4874\u201381.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2457_CR63","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/stem.160413","volume":"16","author":"JS Ross","year":"1998","unstructured":"Ross JS, Fletcher JA. The HER-2\/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998;16(6):413\u201328.","journal-title":"Stem Cells"},{"issue":"3","key":"2457_CR64","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.urology.2007.01.053","volume":"69","author":"LJ Costa","year":"2007","unstructured":"Costa LJ, Gemmill RM, Drabkin HA. Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. Urology. 2007;69(3):596\u2013602.","journal-title":"Urology"},{"key":"2457_CR65","unstructured":"Jang IS, Neto EC, Guinney J, Friend SH, Margolin AA. Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data. Pac Symp Biocomput. 2014;63\u201374."},{"issue":"1","key":"2457_CR66","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10107-012-0540-0","volume":"141","author":"E Cand\u00e8s","year":"2013","unstructured":"Cand\u00e8s E, Recht B. Simple bounds for recovering low-complexity models. Math Program. 2013;141(1):577\u201389.","journal-title":"Math Program"},{"key":"2457_CR67","doi-asserted-by":"publisher","unstructured":"Wang K. MCLRP: Codes and datasets for predicting drug response. Zenodo; 2025. Available from: https:\/\/doi.org\/10.5281\/zenodo.8127448.","DOI":"10.5281\/zenodo.8127448"},{"key":"2457_CR68","unstructured":"Wang K. MCLRP: A low-rank completion model for drug response prediction. GitHub; 2025. Available from: https:\/\/github.com\/kunwangouc\/MCLRP."},{"key":"2457_CR69","unstructured":"Broad Institute. Cancer Cell Line Encyclopedia (CCLE). Broad Institute; 2019. Available from: https:\/\/www.broadinstitute.org\/ccle."},{"key":"2457_CR70","unstructured":"Genomics of Drug Sensitivity in Cancer Consortium. Genomics of Drug Sensitivity in Cancer (GDSC). CancerRxGene; 2019. Available from: https:\/\/www.cancerrxgene.org."}],"container-title":["BMC Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12915-025-02457-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12915-025-02457-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12915-025-02457-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T15:04:48Z","timestamp":1767798288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12915-025-02457-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2457"],"URL":"https:\/\/doi.org\/10.1186\/s12915-025-02457-8","relation":{},"ISSN":["1741-7007"],"issn-type":[{"value":"1741-7007","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"G.T. and J.L.Y. are employed in Geneis Beijing Co., Ltd., Beijing; Other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}